CD6 and infection: The first evidence for the in vivo therapeutic benefit of the MAMP-binding properties of CD6 in infection was the demonstration of increased survival, concomitant with reduced serum levels of pro-inflammatory cytokines (i.e., TNF-α, IL-6, and IL-1β), following prophylactic infusion of recombinant soluble human CD6 (rshCD6) to mice undergoing a lethal LPS-induced septic shock, an experimental model of severe Gram-negative infection [13].